Senior Executives to Support Company's Growth Opportunities
PORTLAND, Ore., Sept. 25 /PRNewswire/ --
Bioject Medical Technologies Inc. (Nasdaq: BJCT), a leading developer of
needle-free drug delivery systems, today announced the hiring of two senior
executives. John Gandolfo, 40, has been named chief financial officer of the
company and Michael Temple, 51, has been named executive vice president and
general manager.
John Gandolfo has more than 15 years of experience as a chief financial
officer of rapidly growing public and private businesses with a primary focus
in the medical sector. From April 1994 through November 1999, Mr. Gandolfo
was chief financial officer of Impath, Inc., a publicly held, cancer-focused
healthcare information company. Immediately prior to joining Bioject,
Mr. Gandolfo was chief financial officer of Capital Access Network, a
specialty finance corporation. A graduate of Rutgers University, Mr. Gandolfo
is a certified public accountant who began his professional career at Price
Waterhouse.
"John Gandolfo has an exceptionally strong financial background with
public companies in the healthcare industry including expertise in the
structuring of partnerships and affiliations with major biotech and
pharmaceutical corporations. He brings a wealth of experience in finance and
well-developed Wall Street connections," said Jim O'Shea, chairman, president
and chief executive officer.
Mike Temple was most recently founder and CFO of Upright Systems Inc., an
internet infrastructure company. Prior to Upright Systems, Mr. Temple was
Bioject's chief financial officer. Mr. Temple's additional experience
includes serving as chief financial officer of both Instromedix, Inc., a
Portland-based medical technology company, and of the Yoshida Group, a
Portland-based manufacturing and service conglomerate. Prior to joining the
Yoshida Group, Mr. Temple was a principal in the accounting and business
advisory services practice of Laventhol & Horvath, a national public
accounting firm. He is a Certified Public Accountant and holds a bachelor's
degree in business administration from the University of Portland.
"In addition to his financial background, Mike brings substantial
manufacturing and operating expertise to the company," noted Jim O'Shea. "He
will have primary responsibility for operations and we are looking for him to
expand both our manufacturing and product development capabilities to meet the
growing demands being placed on those two functions."
"These two key hires will add additional strength to an already strong
executive group and will identify and implement financial strategies, elevate
the company's visibility in the investment community and prepare the company
to effectively manage the growing demand that will be placed on our product
development and manufacturing resources by both current and anticipated future
customers."
About Bioject
Bioject Medical Technologies Inc., based in Portland, Oregon, is an
innovative developer and manufacturer of needle-free drug delivery systems.
Needle-free injection works by forcing medication at high speed through a tiny
orifice held against the skin. This creates a fine stream of high-pressure
fluid penetrating the skin and depositing medication in the tissue beneath.
The company is focused on developing mutually beneficial agreements with
leading pharmaceutical and biotechnology companies. Bioject's partners now
include Amgen and Serono.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors,
including anticipated future demand for the company's products, which may
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance, or achievements expressed or implied by such forward looking
statements. Readers of this press release are referred to the Company's
filings with the Securities and Exchange Commission, including the company's
Annual Report on Form 10-K for the year ended March 31, 2001 for further
discussions of factors which could affect future results. Forward-looking
statements are based on the estimates and opinions of management on the date
the statements are made. The company assumes no obligation to update
forward-looking statements if conditions or management's estimates or opinions
should change.
More information can be found at Bioject's home page at:
http://www.bioject.com/ .
SOURCE Bioject Medical Technologies, Inc.
 back to top
Related links:
http://www.bioject.com
Company News On-Call:
http://www.prnewswire.com/gh/cnoc/comp/101750.html
CONTACT:
Jim O'Shea, Chairman, President & CEO of
Bioject Medical Technologies Inc., +1-503-639-7221, ext. 565; or
IR/Media, Jim Flanagan of IR Strategic Advisors, +1-781-863-1333,
or jflanagan@iradvisors.com, for Bioject Medical Technologies
Inc.
|
